0001172661-15-001253.txt : 20150626 0001172661-15-001253.hdr.sgml : 20150626 20150626165711 ACCESSION NUMBER: 0001172661-15-001253 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20150626 DATE AS OF CHANGE: 20150626 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Biotie Therapies Corp. CENTRAL INDEX KEY: 0001579695 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: H9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-88895 FILM NUMBER: 15955818 BUSINESS ADDRESS: STREET 1: JOUKAHAISENKATU 6 CITY: TURKU STATE: H9 ZIP: FI-20520 BUSINESS PHONE: 358-2-274-8900 MAIL ADDRESS: STREET 1: JOUKAHAISENKATU 6 CITY: TURKU STATE: H9 ZIP: FI-20520 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ORBIMED ADVISORS LLC CENTRAL INDEX KEY: 0001055951 IRS NUMBER: 133976876 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 601 LEXINGTON AVENUE STREET 2: 54TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 739-6400 MAIL ADDRESS: STREET 1: 601 LEXINGTON AVENUE STREET 2: 54TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 SC 13G 1 biti061915.htm SCHEDULE 13G HOLDINGS REPORT

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. )*



 

Biotie Therapies Oyj
(Name of Issuer)

 

 

Common Stock
(Title of Class of Securities)

 

 

09074D103
(CUSIP Number)

 

 

June 16, 2015
(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o Rule 13d-1(b)

x Rule 13d-1(c)

o Rule 13d-1(d)

 

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 

 

CUSIP No. 09074D103
 SCHEDULE 13G
Page 2 of 9 Pages
         
1
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) 
 
OrbiMed Capital GP V LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
73,438,204(1)
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
73,438,204(1)
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
73,438,204(1)
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
7.49%*
12
TYPE OF REPORTING PERSON (See Instructions)
 
OO

(1) Evidenced by (i) 51,944,444 shares of Common Stock and (ii) 268,672 American Depositary Shares ("ADSs"); each ADS represents eighty shares of Common Stock.

 

*This percentage is calculated based upon 980,851,935 of the Issuer's Common Stock outstanding (including any such Common Stock represented by ADSs), as set forth in the Issuer's final prospectus, dated June 10, 2015, filed with the Securities and Exchange Commission on June 12, 2015, and taking into account the underwriters' full exercise of their over-allotment option to purchase up to 44,629 ADSs as announced by the Issuer on June 12, 2015.

 

CUSIP No. 09074D103
 SCHEDULE 13G
Page 3 of 9 Pages
         
1
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) 
 
OrbiMed Advisors LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
73,438,204(1)
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
73,438,204(1)
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
73,438,204(1)
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
7.49%*
12
TYPE OF REPORTING PERSON (See Instructions)
 
IA

(1) Evidenced by (i) 51,944,444 shares of Common Stock and (ii) 268,672 American Depositary Shares ("ADSs"); each ADS represents eighty shares of Common Stock.

 

*This percentage is calculated based upon 980,851,935 of the Issuer's Common Stock outstanding (including any such Common Stock represented by ADSs), as set forth in the Issuer's final prospectus, dated June 10, 2015, filed with the Securities and Exchange Commission on June 12, 2015, and taking into account the underwriters' full exercise of their over-allotment option to purchase up to 44,629 ADSs as announced by the Issuer on June 12, 2015.

 
 

 

CUSIP No. 09074D103
 SCHEDULE 13G
Page 4 of 9 Pages
         
1
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) 
 
Samuel D. Isaly
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
73,438,204(1)
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
73,438,204(1)
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
73,438,204(1)
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
7.49%*
12
TYPE OF REPORTING PERSON (See Instructions)
 
IN

(1) Evidenced by (i) 51,944,444 shares of Common Stock and (ii) 268,672 American Depositary Shares ("ADSs"); each ADS represents eighty shares of Common Stock.

 

*This percentage is calculated based upon 980,851,935 of the Issuer's Common Stock outstanding (including any such Common Stock represented by ADSs), as set forth in the Issuer's final prospectus, dated June 10, 2015, filed with the Securities and Exchange Commission on June 12, 2015, and taking into account the underwriters' full exercise of their over-allotment option to purchase up to 44,629 ADSs as announced by the Issuer on June 12, 2015.

 

 

CUSIP No.  09074D103
 SCHEDULE 13G
Page 5 of 9 Pages

 

Item 1.(a) Name of Issuer:

Biotie Therapies Oyj

(b) Address of Issuer’s Principal Executive Offices:

Joukahaisenkatu 6

FI-20520 Turku

Finland

Item 2.(a) Name of Person Filing:

This Schedule 13G is being filed by each of the following persons (each a “Reporting Person”, and together, the “Reporting Persons”):

(i) OrbiMed Capital GP V LLC ("GP V")

(ii) OrbiMed Advisors LLC ("Advisors")

(iii) Samuel D. Isaly ("Isaly")

(b) Address of Principal Business Office:

601 Lexington Avenue, 54th Floor

New York, NY 10022

(c) Citizenship:

Please refer to Item 4 on each cover sheet for each filing person.

 (d) Title of Class of Securities:

Common Stock

 (e) CUSIP No.:

09074D103

 
 

 

CUSIP No. 09074D103
 SCHEDULE 13G
Page 6 of 9 Pages

 

 

Item 3.

Not Applicable

 
 

 

CUSIP No. 09074D103
 SCHEDULE 13G
Page 7 of 9 Pages

 

 

Item 4. Ownership:

 

GP V is the sole general partner of OrbiMed Private Investments V, LP ("OPI V"), which holds 73,438,204 shares of Common Stock ("Shares"). Advisors is an investment advisor in accordance with § 240.13d-1(b)(1)(ii)(E) and is the Managing Member of GP V. Isaly is the Managing Member of Advisors and a control person in accordance with § 240.13d-1(b)(1)(ii)(G). On the basis of these relationships, GP V, Advisors and Isaly may be deemed to share beneficial ownership of the Shares held by OPI V.

 

(a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).

(b) Percent of class: See the response(s) to Item 11 on the attached cover page(s).

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:See the response(s) to Item 5 on the attached cover page(s).

(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).

(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).

(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

 

See Item 4.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

 

Not Applicable.

Item 9. Notice of Dissolution of Group.

 

Not Applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 
 
CUSIP No. 09074D103
 SCHEDULE 13G
Page 8 of 9 Pages

 

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: June 26, 2015

 

 

  OrbiMed Capital GP V LLC
  By: OrbiMed Advisors LLC, its Managing Member
       
  By: /s/ Samuel D. Isaly
    Name:  Samuel D. Isaly
    Title:  Managing Member
       
  OrbiMed Advisors LLC
       
  By: /s/ Samuel D. Isaly
    Name:  Samuel D. Isaly
    Title:  Managing Member
       
  Samuel D. Isaly
 
  /s/ Samuel D. Isaly
    Name:  Samuel D. Isaly

 

 
 
 
 
CUSIP No.  09074D103
 SCHEDULE 13G
Page 9 of 9 Pages

 

 

EXHIBIT A

JOINT FILING AGREEMENT

 

The undersigned hereby agree that the Statement on this Schedule 13G dated June 26, 2015 (the "Schedule 13G"), with respect to the Common Stock of Biotie Therapies Oyj is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of June 26, 2015.

 

 

  OrbiMed Capital GP V LLC
  By: OrbiMed Advisors LLC, its Managing Member
       
  By: /s/ Samuel D. Isaly
    Name:  Samuel D. Isaly
    Title:  Managing Member
       
  OrbiMed Advisors LLC
       
  By: /s/ Samuel D. Isaly
    Name:  Samuel D. Isaly
    Title:  Managing Member
       
  Samuel D. Isaly
 
  /s/ Samuel D. Isaly
    Name:  Samuel D. Isaly